A 62-year-old man comes to the clinic for a routine follow-up. He has a history of type 2 diabetes mellitus, hyperlipidemia, and hypertension. His current medications include metformin, atorvastatin, lisinopril, and amlodipine. He brings a magazine advertisement for a newly approved adjunctive cardiovascular medication, 'Lipozon,' which claims to 'reduce the risk of major adverse cardiovascular events (MACE) by 33%!'
The physician reviews the FDA package insert and the pivotal randomized controlled trial (RCT) summary provided in the literature.
| Study Parameter | Lipozon + Standard Therapy (n=3000) | Placebo + Standard Therapy (n=3000) |
|---|---|---|
| 5-Year MACE Incidence | 4.0% | 6.0% |
| ALT/AST > 3x ULN | 2.5% | 0.5% |
| CYP3A4 Inhibition | Strong | None |
The patient's recent laboratory results show an AST of 32 U/L and ALT of 35 U/L (both within normal limits). He asks if he should add this medication to his regimen.
Based on the provided literature data and the patient's medical history, which of the following is the most appropriate recommendation regarding the addition of this medication?
- AAdvise adding the medication because the 33% absolute risk reduction provides a substantial clinical benefit that outweighs the slight increase in transaminases
- BAdvise adding the medication because only 3 patients need to be treated to prevent one major adverse cardiovascular event
- CAdvise adding the medication but closely monitor liver enzymes, as the absolute risk reduction of 2% justifies its use despite the increased risk of hepatotoxicity
- Advise against adding the medication because the absolute risk reduction is only 2% and it poses a high risk of drug-drug interactions with his current lipid-lowering therapyAnswer
- EAdvise against adding the medication because its concomitant use with his current antihyperglycemic agent causes an unacceptable synergistic risk of hepatic failure